Bli medlem
Bli medlem

Du är här

2015-04-23

ThromboGenics NV: ThromboGenics Starts Evaluating JETREA® for the Treatment of Retinal Vein Occlusion (RVO)

Company receives
€ 0.6 million research grant from IWT,
the Flemish Agency for Innovation by Science and Technology

Leuven, April 23, 2015
- ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical
company focused on developing and commercializing innovative medicines for
the treatment of vitreo-retinal diseases, today announces that it is
evaluating JETREA®(ocriplasmin) as a potential treatment for Retinal Vein
Occlusion (RVO).

RVO is the third indication ThromboGenics has underway for JETREA®.

The new research will build on earlier ThromboGenics Phase IIa data pointing
out the potential of ocriplasmin (formerly known as microplasmin) for the
treatment of peripheral arterial occlusions. With this new vitreo-retinal
project, ThromboGenics will demonstrate the potential of using locally
delivered ocriplasmin for lysing the blood clots (in the retinal veins) that
are responsible for this sight threatening condition.

In support of this research, ThromboGenics has secured a €0.6 million grant
from the Flemish Agency for Innovation by Science and Technology (IWT). The
Company will use this grant to evaluate ocriplasmin's ability to lyse the
clots that cause RVO by local intravenous administration of this thrombolytic
agent in pre-clinical models of the disease. For that, the Company will
collaborate with the Ophthalmology Department of the University Hospital
UZLeuven in Belgium.

The grant will also support a partnership of ThromboGenics with the Mechanical
Engineering Department of the KU Leuven. The Department is developing a
robotic-assisted system which has the capacity to deliver local
administration of ocriplasmin in the retinal veins.

At present, there is no treatment option for clearing retinal veins of
RVO-patients. The current standard of care for RVO primarily focuses on the
treatment of visual impairment due to macular edema resulting from an
existing retinal vein occlusion (central or branch retinal vein occlusion).
Although the current treatment paradigm improves the vision of the patient,
it comes with a relatively high cost associated with continued drug
administrations and follow up by the physician.

"Retinal Vein Occlusion (RVO) is known to be the second most common retinal
vascular disease, and thought to negatively impact the quality of life of 16
million patients worldwide
, saysProf Dr Peter Stalmans of the Department of Ophthalmology of UZLeuven.
RVO, caused by the formation of clots in either the central retinal vein or
in
branch retinal veins, profoundly affects visual acuity. I'm looking forward
to work with ThromboGenics and the robotics experts from the Mechanical
Engineering Department of KU Leuven, for the evaluation of ocriplasmin as a
potential new treatment of RVO,"
he concludes.

Dr Patrik De Haes, CEO of ThromboGenics,
said,"We are very happy to announce the start of the development of
JETREA®for this third indication.
We believe that, when delivered locally, the proven clot busting capabilities
of
JETREA®really hold the potential for our drug to become an effective treatment
for
the many patients globally who suffer from RVO."

End

ThromboGenics is a partner of the Leuven Retina Meeting 2015, in Leuven, from
23 to 25 April, 2015. More information atwww.LeuvenRetinaMeeting.eu

For further information please contact:

----------------------------------------------------------------------------------------------------------------
| ThromboGenics Citigate Dewe Rogerson |
| |
| |
|Wouter Piepers, Global Head of Corporate Communications&Investor Relations David Dible/ Malcolm Robertson |
| |
|+32 16 75 13 10 / +32 478 33 56 32 Tel: +44 20 7282 2867 |
| |
|wouter.piepers@thrombogenics.com malcolm.robertson@citigatedr.co.uk |
----------------------------------------------------------------------------------------------------------------

About
JETREA
®(ocriplasmin)

JETREA®(ocriplasmin) is a truncated form of human plasmin. JETREA®acts as a
selective proteolytic enzyme that cleaves fibronectin, laminin and collagen,
three major components of the vitreoretinal interface that play an important
role in vitreomacular adhesion.

In the US, JETREA®is indicated for the treatment of symptomatic vitreomacular
adhesion. In Europe, JETREA®is indicated for the treatment of vitreomacular
traction (VMT), including when associated with macular hole of diameter less
than or equal to 400 microns.

JETREA®was evaluated in two multi-center, randomized, double-masked Phase III
trials conducted in the U.S. and Europe involving 652 patients with
vitreomacular adhesion. Both studies met the primary endpoint of resolution
of VMA at day 28. This Phase III program found that 26.5% of patients treated
with ocriplasmin saw resolution of VMA, compared with 10.1% of patients
receiving placebo (p<0.01). The Phase III program also showed that JETREA was
generally well tolerated with most adverse events being transient and mild in
severity.

In March 2015, ThromboGenics reported top line results from OASIS, a Phase
IIIb study. This randomized, sham controlled, double masked study followed-up
patients for 24 months post injection. In this study, retina physicians were
able to use us SD-OCT to select patients with focal VMA and patients without
Epiretinal Membrane (ERM), two criteria which have been shown to lead to
better treatment outcomes with JETREA®. OASIS data have shown to include
still over 20% ERM patients.

The trial showed that 41.7% of patients treated with JETREA® achieved VMA
resolution at Day 28 post injection compared with only 6.2% of patients who
received a sham injection (p<0.001); and that the drug's safety profile in
the 24 month follow period was consistent with the drug's overall safety
profile as known from the approved label.

About ThromboGenics

ThromboGenics is an integrated biopharmaceutical company focused on developing
and commercializing innovative ophthalmic and oncology medicines. The
Company's lead product, JETREA®(ocriplasmin) was approved by the US FDA for
the treatment of symptomatic VMA and was launched by ThromboGenics in January
2013.

ThromboGenics signed a strategic partnership with Alcon, a division of
Novartis, for the commercialization of JETREA®outside the United States in
2012. To-date JETREA®has been approved in over 50 countries globally.

JETREA®is currently being evaluated for two further indications, diabetic
retinopathy (DR) and retinal vein occlusion (RVO).

ThromboGenics is the major shareholder in Oncurious NV, a cancer focused
company that was formed in conjunction with VIB, a leading life science
institute in Flanders (Belgium). Oncurious was created to develop TB-403,
initially for medulloblastoma, the most frequent form of pediatric brain
cancer. ThromboGenics has retained the exclusive rights to use TB-403 for
ophthalmic indications.

ThromboGenics is headquartered in Leuven, Belgium, and has offices in Iselin,
NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext
Brussels exchange under the symbol THR. More information is available
atwww.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking".
Such forward-looking statements are based on current expectations, and,
accordingly, entail and are influenced by various risks and uncertainties.
The Company therefore cannot provide any assurance that such forward-looking
statements will materialize and does not assume an obligation to update or
revise any forward-looking statement, whether as a result of new information,
future events or any other reason. Additional information concerning risks
and uncertainties affecting the business and other factors that could cause
actual results to differ materially from any forward-looking statement is
contained in the Company's Annual Report.

This press release does not constitute an offer or invitation for the sale or
purchase of securities or assets of ThromboGenics in any jurisdiction. No
securities of ThromboGenics may be offered or sold within the United States
without registration under the U.S. Securities Act of 1933, as amended, or in
compliance with an exemption therefrom, and in accordance with any applicable
U.S. state securities laws.

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ThromboGenics NV via Globenewswire

HUG#1913616

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.